U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

– First Agent Indicated for Uninfected Adolescents at Risk of Acquiring HIV – FOSTER CITY, Calif.–(BUSINESS WIRE)–May 15, 2018– Gilead Sciences, Inc.(Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

— Facilities in the Netherlands and the United States Will Help Advance Manufacturing of Cell Therapies for People with Cancer — SANTA MONICA, Calif.–(BUSINESS WIRE)–May 15, 2018– Kite, a Gilead Company(Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer

Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16

Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif.–(BUSINESS WIRE)–May 8, 2018– Gilead Sciences, Inc.(Nasdaq:GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development, will

Gilead Publishes 2017 Year in Review

FOSTER CITY, Calif., May 2, 2018 — Gilead Sciences, Inc. today announced the release of its 2017 Year in Review, composed of its Annual Report and Corporate Social Responsibility report. The Year in Review provides a comprehensive view into the company’s

Gilead Sciences Announces Second Quarter 2018 Dividend

FOSTER CITY, Calif.–(BUSINESS WIRE)–May 1, 2018– Gilead Sciences, Inc.(Nasdaq:GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the second quarter of 2018. The dividend is payable on June 28, 2018, to

Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases

— Verily to Deploy Its Immunoscape™ Platform to Generate Insights from Gilead Clinical Trials — FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Apr. 30, 2018– Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using

European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

– In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks – FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 27, 2018– Gilead Sciences, Inc.(NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency(EMA),

Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018

— Combination Therapy Data Presented from First 12-Week Study — — Enrollment Complete for Phase 3 STELLAR Trials of ASK1 Inhibitor Selonsertib — FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 13, 2018– Gilead Sciences, Inc.(Nasdaq: GILD) today presented data from a proof-of-concept study of